gefitinib has been researched along with su 6656 in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (su 6656) | Trials (su 6656) | Recent Studies (post-2010) (su 6656) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 154 | 0 | 73 |
| Protein | Taxonomy | gefitinib (IC50) | su 6656 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.1 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.15 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.17 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.02 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.13 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.77 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1765 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 8.7 | |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.11 | |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | 0.1 | |
| Aurora kinase B | Homo sapiens (human) | 0.019 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.85 | |
| Aurora kinase C | Homo sapiens (human) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Lin, J; Shen, W; Sun, J; Xue, J; Zhang, C; Zhang, X | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
3 other study(ies) available for gefitinib and su 6656
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Molecular Docking Simulation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |